Understand Medicare Part D’s design and its coverage gap to offer the most affordable prescription drug options for patients.
Medicare Part D has reduced-but not solved-the problem of out-of-pocket pharmacy costs for older adults with diabetes, according to a study published online in Diabetes Care.
Smaldone
“Managed care executives should be interested because diabetes affects approximately 25% of Medicare beneficiaries,” says study author Arlene Smaldone, PhD, CPNP, CDE, associate professor of nursing at at Columbia University School of Nursing. “Our study found that while the Part D benefit has overall reduced out-of-pocket costs for older adults with diabetes, approximately 40% continue to enter or exceed the ‘donut-hole’ period.”
Using data from the Medical Expenditure Panel survey, Smaldone, and colleagues, examined the proportion of out-of-pocket pharmacy costs for Medicare beneficiaries before and after implementation of the Part D benefit and compared them to the proportion of out-of-pocket pharmacy expenditures for those age 50 to 60 years old who were not eligible for the Medicare benefit. The effect of the Medicare Part D benefit over time was statistically modeled using an interrupted time series analysis and the net benefit attributed to the Part D benefit was analyzed using a difference-in-difference approach.
The study found that after implementation of Medicare Part D, the proportion of out-of-pocket pharmacy costs was lower for Medicare beneficiaries (29.2%) compared to the younger comparison group (37.7%).
“Uptake of Medicare Part D benefit was utilized by those who lacked access prior to the benefit: women, blacks and Hispanics and those who had reported problems in getting their medications prior to Part D,” Smaldone, assistant dean, scholarship and research, Columbia University School of Nursing, tells Managed Healthcare Executive.
Additionally, over the period 2006 to 2011, the Part D benefit reduced out of pocket costs for prescription drugs by 19.4%.
The Medicare Part D pharmacy benefit was the first major policy change to Medicare since its inception, according to Smaldone.
“However, the benefit does not fully cover cost of prescription drugs, has a donut-hole period where beneficiaries are responsible for the full cost of their drugs and poses risk of poor medication adherence due to inability to pay these costs,” she says. “While Part D has been previously studied, it has not been well studied in older adults with diabetes. We were interested in how the benefit has worked for older adults with diabetes and the proportion of older adults with diabetes who were vulnerable to the donut hole.”
Based on the study, Smaldone offers four takeaways:
1. The Part D benefit has reduced but not solved the problem of out-of-pocket costs for older adults with diabetes.
2. Entry into the donut-hole period makes elders vulnerable to poor medication adherence through inability to pay full cost of medications thereby posing risks to health.
3. While efforts are currently under way through the Affordable Care Act to close the donut-hole gap, full achievement of these efforts and its effects on out-of-pocket costs for older adults with diabetes remain uncertain.
4. To reduce the risks of cost-related medication nonadherence, healthcare providers must understand Medicare Part D’s design and its coverage gap to offer the most affordable prescription drug options for their patients.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More